1620 Investment Advisors, Inc. Avadel Pharmaceuticals PLC Transaction History
1620 Investment Advisors, Inc.
- $124 Million
- Q3 2024
A detailed history of 1620 Investment Advisors, Inc. transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 1,000 shares of AVDL stock, worth $10,930. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,000
Previous 1,000
-0.0%
Holding current value
$10,930
Previous $14,000
7.14%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding AVDL
# of Institutions
8Shares Held
1.07MCall Options Held
0Put Options Held
0-
Knoll Capital Management, LLC Miami, FL600KShares$6.56 Million3.88% of portfolio
-
Knott David M Jr Syosset, NY332KShares$3.63 Million1.53% of portfolio
-
Schulhoff & CO Inc137KShares$1.5 Million0.81% of portfolio
-
American Portfolios Advisors Holbrook, NY500Shares$5,4650.0% of portfolio
-
American Research & Management Co.100Shares$1,0930.0% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $662M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...